Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 3/2013

01-06-2013 | REVIEW ARTICLE

Amiodarone-Induced Pulmonary Toxicity—A Fatal Case Report and Literature Review

Authors: Felix T. Range, Ekkehard Hilker, Günter Breithardt, Boris Buerke, Pia Lebiedz

Published in: Cardiovascular Drugs and Therapy | Issue 3/2013

Login to get access

Abstract

Amiodarone is a widely used and very potent antiarrhythmic substance. Among its adverse effects, pulmonary toxicity is the most dangerous without a causal treatment option. Due to a very long half-life, accumulation can only be prevented by strict adherence to certain dosage patterns. In this review, we outline different safe and proven dosing schemes of amiodarone and compare the incidence and description of pulmonary toxicity. Reason for this is a case of fatal pulmonary toxicity due to a subacute iatrogenic overdosing of amiodarone in a 74-year-old male patient with known severe coronary artery disease, congestive heart failure and ectopic atrial tachycardia with reduced function of kidneys and liver but without preexisting lung disease. Within 30 days, the patient received 32.2 g of amiodarone instead of 15.6 g as planned. Despite early corticosteroid treatment after fast exclusion of all other differential diagnoses, the patient died another month later in our intensive care unit from respiratory failure due to bipulmonal pneumonitis.
Literature
1.
go back to reference Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest. 1988;93:1242–8.PubMedCrossRef Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest. 1988;93:1242–8.PubMedCrossRef
2.
go back to reference Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711–8.PubMedCrossRef Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711–8.PubMedCrossRef
3.
go back to reference Navarro-López F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am J Cardiol. 1993;72:1243–8.PubMedCrossRef Navarro-López F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am J Cardiol. 1993;72:1243–8.PubMedCrossRef
4.
go back to reference Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–8.PubMedCrossRef Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–8.PubMedCrossRef
5.
go back to reference Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349:675–82.PubMedCrossRef Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349:675–82.PubMedCrossRef
6.
go back to reference Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997;349:667–74.PubMedCrossRef Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997;349:667–74.PubMedCrossRef
7.
go back to reference Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41:1707–12.PubMedCrossRef Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41:1707–12.PubMedCrossRef
8.
go back to reference Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.PubMedCrossRef Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.PubMedCrossRef
9.
go back to reference Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.PubMedCrossRef Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.PubMedCrossRef
10.
go back to reference Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–94.PubMedCrossRef Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–94.PubMedCrossRef
11.
go back to reference Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.PubMedCrossRef Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.PubMedCrossRef
12.
go back to reference Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within 2 weeks of initiation of amiodarone. Am J Cardiol. 2002;89:896–8.PubMedCrossRef Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within 2 weeks of initiation of amiodarone. Am J Cardiol. 2002;89:896–8.PubMedCrossRef
13.
go back to reference Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines. Circulation. 2006;114:e257–354.PubMedCrossRef Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines. Circulation. 2006;114:e257–354.PubMedCrossRef
14.
go back to reference Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Hear Rhythm. 2007;4:1250–9.CrossRef Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Hear Rhythm. 2007;4:1250–9.CrossRef
16.
go back to reference Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245–53.PubMedCrossRef Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245–53.PubMedCrossRef
17.
go back to reference Tuseth V, Jaatun HJ, Dickstein K. Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. Heart. 2005;91:964–5.PubMedCrossRef Tuseth V, Jaatun HJ, Dickstein K. Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. Heart. 2005;91:964–5.PubMedCrossRef
19.
go back to reference Ashrafian H, Davey P. Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest. 2001;120:275–82.PubMedCrossRef Ashrafian H, Davey P. Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest. 2001;120:275–82.PubMedCrossRef
20.
21.
go back to reference Rotmensch HH, Liron M, Tupilski M, Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J. 1980;100:412–3.PubMedCrossRef Rotmensch HH, Liron M, Tupilski M, Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J. 1980;100:412–3.PubMedCrossRef
22.
go back to reference Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417–24. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417–24.
23.
go back to reference Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51–9.PubMedCrossRef Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51–9.PubMedCrossRef
24.
go back to reference Heger JJ, Prystowsky EN, Zipes DP. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J. 1983;106:931–5.PubMedCrossRef Heger JJ, Prystowsky EN, Zipes DP. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J. 1983;106:931–5.PubMedCrossRef
25.
go back to reference Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101:462–9.PubMed Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101:462–9.PubMed
26.
27.
go back to reference Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology. 1990;177:121–5.PubMed Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology. 1990;177:121–5.PubMed
28.
go back to reference Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J. 1983;106:906–16.PubMedCrossRef Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J. 1983;106:906–16.PubMedCrossRef
29.
go back to reference Rote Liste 2011. Arzneimittelinformation für Deutschland. Frankfurt/Main: Rote Liste Service GmbH; 2011. Rote Liste 2011. Arzneimittelinformation für Deutschland. Frankfurt/Main: Rote Liste Service GmbH; 2011.
30.
go back to reference Libby P, Bonow RO, Zipes DP, Mann DL, eds. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelhia: Saunders; 2008. Libby P, Bonow RO, Zipes DP, Mann DL, eds. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelhia: Saunders; 2008.
31.
go back to reference Camm J, Lüscher TF, Serruys PW. The ESC textbook of cardiovascular medicine. 2nd ed. New York: Oxford University Press; 2009. Camm J, Lüscher TF, Serruys PW. The ESC textbook of cardiovascular medicine. 2nd ed. New York: Oxford University Press; 2009.
32.
go back to reference Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92:3264–72.PubMedCrossRef Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92:3264–72.PubMedCrossRef
33.
go back to reference Kalbfleisch SJ, Williamson B, Man KC, et al. Prospective, randomized comparison of conventional and high dose loading regimens of amiodarone in the treatment of ventricular tachycardia. JACC. 1993;22:1723–9.PubMedCrossRef Kalbfleisch SJ, Williamson B, Man KC, et al. Prospective, randomized comparison of conventional and high dose loading regimens of amiodarone in the treatment of ventricular tachycardia. JACC. 1993;22:1723–9.PubMedCrossRef
34.
go back to reference Collaborative Group for Amiodarone Evaluation. Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Am J Cardiol. 1984;53:1564–9. Collaborative Group for Amiodarone Evaluation. Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Am J Cardiol. 1984;53:1564–9.
35.
go back to reference Ahmed S, Ranchor AV, Crijns HJGM, Van Veldhuisen DJ, Van Gelder IC, investigators ftC. Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace. 2010;12:785–91. Ahmed S, Ranchor AV, Crijns HJGM, Van Veldhuisen DJ, Van Gelder IC, investigators ftC. Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace. 2010;12:785–91.
Metadata
Title
Amiodarone-Induced Pulmonary Toxicity—A Fatal Case Report and Literature Review
Authors
Felix T. Range
Ekkehard Hilker
Günter Breithardt
Boris Buerke
Pia Lebiedz
Publication date
01-06-2013
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2013
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-013-6446-0

Other articles of this Issue 3/2013

Cardiovascular Drugs and Therapy 3/2013 Go to the issue